Permixon Capsules 160mg N30
Condition: New product
986 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Palm Creeping Fruit Extract
Release form
Capsules
Composition
Active ingredient: Palms of a creeping fruit extract (Serenoa repens fructuum extract); Concentration of active ingredient (mg): 160
Pharmacological effect
Lipidosterol extract of palm fruit Serenoa repens. It has anti-androgenic, anti-inflammatory, anti-edema and anti-proliferative effects, selectively manifesting at the level of the prostate gland. In this case, the drug does not affect the level of sex hormones in the blood plasma, does not affect the potency and libido, and does not change the level of prostate-specific antigen in the blood plasma .; The mechanism of local antiandrogenic action is due to the inhibition of the synthesis of dihydrotestosterone (due to the inhibition of the enzyme 5-alpha reductase types I and II) and its fixation to the cytosolic receptors, which prevents the penetration of the hormone into the nucleus. As a result, protein synthesis is reduced. The mechanism of local anti-inflammatory action is due to the fact that Serenoa repens lipidosterol extract inhibits the activity of phospholipase A2 and the release of arachidonic acid, thereby reducing the synthesis of prostaglandins and leukotrienes, which are mediators of inflammation. During the first weeks of therapy, Permixon reduces capillary permeability and vascular stasis, reduces puffiness and inflammation in the prostate, eliminates compression of the bladder neck and urinary canal, improving urodynamic indices .; Local antiproliferative effect of the drug is manifested by a decrease in the activity of growth factors (primarily epidermal and fibroblastic) and an acceleration of apoptosis of prostate cells, which is reflected in growth inhibition and a subsequent decrease in the volume of the prostate gland .; Thus, Permixon helps, on the one hand, to reduce the severity of the pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nocturia, painful feelings and tension during urination, incomplete emptying of the bladder), and increase urinary volume and strength. On the other hand, against the background of the drug use, further growth and an increase in the volume of the prostate gland are somewhat slowed down.
Pharmacokinetics
Data on the pharmacokinetics of the drug Permixon is not provided.
Indications
Benign hyperplasia (adenoma) of the prostate gland stage I and II.
Contraindications
Hypersensitivity to the drug.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Dosage and administration
The optimal treatment regimen is established individually, on the basis of a diagnostic examination .; The daily dose is 320 mg. It is recommended to take 160 mg (2 pills or 1 capsules) 2 times / day or 320 mg (4 pills or 2 capsules) in 1 dose .; The duration of treatment is at least 3 months. If necessary, repeated courses of therapy.
Side effects
In some cases: nausea, heartburn, gastralgia (usually taking place while taking the drug during a meal).
Overdose
Currently, no cases of overdose of Permixon have been reported .; In case of accidental ingestion of large quantities of the drug, it is necessary to carry out a gastric lavage.
Interaction with other drugs
Permixon antagonism and drugs from the groups most commonly used in the treatment of this disease: antibiotics, uroseptics and anti-inflammatory drugs have not been identified.
special instructions
Permixon is recommended to be taken during meals.